Non small cell lung cancer outcome

Non small cell lung cancer outcome

Epidermal growth factor receptor mutation, primary cancer pathology, and Recursive partitioning analysis class may be proposed as prognostic factors for intracranial progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients after GKRS for brain metastasis in a study 1).


Retrospective analysis of patients with Non small cell lung cancer (NSCLC) completely resected from lung found a 6.8 % first recurrence rate in the brain 2).

Prognosis better than small cell lung cancer (SCLC).

see also Non small cell lung cancer intracranial metastases outcome.

Between 25% and 30% of non-small cell lung cancer (NSCLC) patients will develop Non small cell lung cancer intracranial metastases.

Frequently they are the first site of recurrence in early-stage NSCLC patients treated with definitive therapies 3) 4) 5) 6) 7).

Non small cell lung cancer outcome is better than small cell lung cancer.

Given uniform staging, treatment, and socioeconomic status the overall survival rates for African American and White patients with NSLC are similar 8)

A significant excess mortality remains in lung cancer after years which may be explained by excess risk of death due to smoking-related comorbidity in these patients. Caregivers should use this information for planning optimal cancer surveillance and informing cancer survivors about their actual prognosis 9).

Retrospective analysis of patients with Non small cell lung cancer completely resected from lung found a 6,8 % first recurrence rate in the brain 10).


1)

Yang SH, Kim HY, Lee SI, Jin SJ. The Effect of Epidermal Growth Factor Receptor Mutation on Intracranial Progression-Free Survival of Non-Small Cell Lung Cancer Patients with Brain Metastasis Underwent Gamma Knife Radiosurgery. Brain Tumor Res Treat. 2020 Oct;8(2):103-108. doi: 10.14791/btrt.2020.8.e15. PMID: 33118342.
2)

Figlin RA, Piantadosi S, Feld R, et al. Intracranial Recurrence of Carcinoma After Complete Resection of Stage I, II, and III Non-Small-Cell Lung Cancer. N Engl J Med. 1988; 318:1300–1305
3)

Schettino C, Bareschino MA, Rossi A, Maione P, Sacco PC, Colantouni G, Rossi E, Gdidelli C. Targeting angiogenesis for treatment of NSCLC brain metastases. Curr Cancer Drugs Targets. 2012;12:289–99.
4)

Sperduto PW, Wang M, Robis HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 2013;85:1312–8.
5)

Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82:282–7.
6)

Villalva C, Duranton-Tanneur V, Guilloteau K, et al. EGRF, KRAS, BRAF and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med. 2013;2:296–304.
7)

Barlesi F, Khobta N, Tablet A, et al. Strategies de prise en charge des metastases cerebrales des maladies atteints de cancers bronchiques primitives. Bull Cancer. 2013;100:303–8.
8)

Bryant AS, Cerfolio RJ. Impact of race on outcomes of patients with non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):711-5. doi: 10.1097/JTO.0b013e31817c60c7. PubMed PMID: 18594315.
9)

Janssen-Heijnen ML, van Steenbergen LN, Steyerberg E, Visser O, De Ruysscher DK, Groen HJ. Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands. J Thorac Oncol. 2012 Mar;7(3):496-502. doi: 10.1097/JTO.0b013e318241f80b. PubMed PMID: 22246194.
10)

Figlin RA, Piantadosi S, Feld R; Lung Cancer Study Group. Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. N Engl J Med. 1988 May 19;318(20):1300-5. PubMed PMID: 2834646.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

WhatsApp WhatsApp us
%d bloggers like this: